Is Seleniso (Civio) covered by health insurance? How much?

Selinexor (Selinexor), trade name XPOVIO, is used as a treatment for multiple myeloma and relapsed /refractory diffuse leukemiaSINE) for n>B cell lymphoma (DLBCL) is currently on the market in China and is included in medical insurance. This move greatly reduces the financial burden on patients and enables more patients to benefit from this advanced treatment modality.

In China, Seleniso (Silvio) has been included in the medical insurance catalog, and patients can purchase the drug through regular domestic channels. After being included in medical insurance, the actual payment amount of patients is effectively controlled, and the general price is about more than 5,000 to 10,000 yuan. The specific costs and reimbursement ratios will vary according to the medical insurance policies of different regions. Therefore, patients should consult their local hospital pharmacy or medical insurance department in detail before using this drug to understand the accurate cost and reimbursement situation.

Overseas, especially in countries such as Laos, there are generic drugs of Selinisol (Sivio) on the market. The price of the Lao version of generic drugs is relatively cheap, about more than 2,000 yuan. Although the price is low, the ingredients of generic drugs are basically the same as those of domestic original drugs, and the efficacy is equivalent. For some patients with limited financial conditions, choosing generic drugs is also a feasible solution. However, when choosing generic drugs, patients should ensure the legality of the purchasing channels and the quality of the drugs to avoid the risks of using counterfeit and substandard drugs.

In short, Seleniso (Silvio) as an effective anti-cancer drug, its domestic launch and medical insurance coverage have brought good news to the majority of patients. Before using this drug, patients are advised to consult their doctor and the medical insurance department in detail to understand the specific costs and reimbursement policies in order to make the most suitable treatment choice for them. At the same time, for patients who are considering using generic drugs, they must ensure the legality of the purchasing channels and the quality of the drugs to ensure the therapeutic effect and their own safety.